News
-
-
-
PRESS RELEASE
Proof-of-Concept Results Show Jaguar Health's Crofelemer Reduced Total Parenteral Nutrition in Third Intestinal Failure Orphan Disease Patient
Initial proof-of-concept results show crofelemer's efficacy in reducing TPN for intestinal failure patients. Jaguar seeking partnerships for drug development and commercialization -
-
-
PRESS RELEASE
Original-Research: Jaguar Health Inc (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research updates Buy recommendation on Jaguar Health Inc (ISIN: US47010C8055) to USD 40 target price post-positive breast cancer trial subgroup results. Plans for FDA approval through pivotal trial and orphan drug designation -
-
-
PRESS RELEASE
Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset
Jaguar Health, Inc. diversifies treasury holdings with long-term digital store of value through including cryptocurrency as a reserve asset. Company aims to safeguard against inflation and assesses potential benefits for core development programs -